Publication & Citation Trends
Most Cited Works
Publications
28 total
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial PDF
Cited by 110
OpenAlex
Abstract CT039: Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)
Cited by 4
Semantic Scholar
1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib OA
Cited by 5
Semantic Scholar
13P Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis OA
Cited by 1
Semantic Scholar
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity. OA
Cited by 18
Semantic Scholar
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer OA
Cited by 26
Semantic Scholar
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib OA
Cited by 39
Semantic Scholar
OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy OA
Cited by 19
Semantic Scholar
Research Topics
Advanced Breast Cancer Therapies
(11)
PI3K/AKT/mTOR signaling in cancer
(10)
Protein Degradation and Inhibitors
(8)
Asthma and respiratory diseases
(3)
DNA Repair Mechanisms
(3)
Frequent Co-Authors
Affiliations
AstraZeneca (United Kingdom)
Tel Aviv University
John Radcliffe Hospital
University of Oxford
AstraZeneca (Singapore)